Get In Touch

Global Peptide Therapeutics Market to be Fueled by Increasing Prevalence of Cancer and Diabetes

The global market for peptide therapeutics market derives much of its demand from the treatment of cancer and diabetes. The rising incidence of these diseases is making way for the advancement of peptide drugs, which in turn is propelling the global peptide therapeutics market. Additionally, the technical advancements in peptide drugs have resulted in a reduction in total production cost, fueling the production process of new peptide drugs.

On the other hand, API manufacturers are facing a tough challenge from the complex structure of peptides. Other than this, the lack of regulatory standards to arbitrate developments in peptide drugs is also hampering the growth of the peptide therapeutics market. However, biotech enterprises are identifying prospects for future growth in collaboration with major pharmaceutical firms across the globe.The global peptide therapeutics market is expected to expand at a CAGR of 2.8% during the period from 2014 to 2020 in order to reach US$23.7 billion by 2020. The market had reached a value of US$18.9 billion in 2013.

Market for Respiratory Disorders Poised to Grow at Highest CAGR between 2014 and 2020

Peptide therapeutics find application in the treatment of various kinds of ailments such as cardiovascular, nervous, gastrointestinal, respiratory, metabolism-related, in addition to cancer, various infections, and pain. The cancer market was the dominant application segment of the peptide therapeutics market in 2013. However, the respiratory disorder market segment is projected to develop at the highest CAGR during the period from 2014 to 2020 owing to the recent approval of lucinactant, sold under the brand name Surfaxin.

The global peptide therapeutics market is analyzed on three fronts: Route of administration, marketing status, and regional distribution of the global industry. Based on route of administration, parenteral and oral are the two segments of this market, while branded peptide therapeutics and generic peptide therapeutics are the segments of the global market on the basis of marketing status. The market for generic peptides is expected to do well in the next few years on account of patent expirations expected in the branded peptide market in the near future.

Asia Pacific to Report Highest Compound Annual Growth Rate from 2014 to 2020 

Regionally, the global peptide therapeutics market is distributed among North America, Europe, Asia Pacific, and the Rest of the World, wherein the global market is dominated by the North American and European markets, which jointly occupy over 60% of the global market. However, in spite of the dominance of these regions in the global market, the peptide therapeutics market in Asia Pacific is poised to grow at the highest CAGR during the period from 2014 to 2020.The peptide therapeutics market in Asia Pacific is majorly driven by the rapid growth of this market in China, India, and Japan. The rise in economic stability and increased awareness pertaining to the treatment of various diseases are the major factors fueling the growth of the market in this region.

Japan is the second largest market in the global individual pharmaceutical industry, whereas China and India have a huge population pool suffering from various diseases and ailments that are cured with the help of peptide therapeutics. These factors are expected to establish Asia Pacific as the most promising market for peptide therapeutics in the near future. China and India are also emerging as some of the largest peptide API suppliers in the world.

Amgen, Inc., Bachem Holding AG, AstraZeneca Plc, CordenPharma Int. GmbH, Ipsen S.A., Eli Lilly and Co., Lonza Group Ltd., Novartis AG, Merck & Co., Inc., Novo Nordisk A/S, Roche Holdings AG, PolyPeptide Group, Sanofi, Millennium Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd. are the major enterprises working in the global peptide therapeutics industry. The market is mostly concentrated as Takeda, Teva, and Novo Nordisk collectively hold more than 50% of the overall peptide therapeutics market.

The forthcoming patent expiry of Copaxone by Teva and Velcade by Millennium Pharma and the projected launch of their generic alternatives are expected to change the dynamics of the global peptide therapeutics market in the near future.

Browse Full Global Peptide Therapeutics Market Report With Complete TOC @

7 of 10 large enterprizes view our ToC to take the right decision.

Get In Touch